Clinical Trial Update: A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1-2 trial of XIAP antisense AEG35156 in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AEG35156 (XIAP antisense oligonucleotide)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Aegera Therapeutics | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: TERMINATED